Psoriatic Arthritis- Secondary Care

Size: px
Start display at page:

Download "Psoriatic Arthritis- Secondary Care"

Transcription

1 Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the psoriatic arthritis is only present in one joint, or not getting worse. Most people with psoriasis should be referred to a Rheumatologist (a hospital consultant that specialises in arthritis) as soon as psoriatic arthritis is suspected. There is no straightforward test to diagnose psoriatic arthritis, and so a Rheumatologist is best placed to confirm a diagnosis, and give advice on treatment options. This information sheet covers Disease Modifying Anti Rheumatic Drugs (DMARDs). These treatments cannot be prescribed by a GP, and are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist and Rheumatologist are present. The DMARD category for psoriatic arthritis includes: Methotrexate Sulfasalazine Leflunomide Apremilast Biologic treatments Cimzia (certolizumab pegol), Cosentyx (secukinumab), Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Stelara (ustekinumab) 1 What are DMARDs? DMARDs are treatments that alter the condition itself, rather than just treat the symptoms. DMARDs work by attacking the causes of inflammation in the joints. They lessen the activity of arthritis by reducing swelling and stiffness, reducing the pain as well. These treatments are different to anti-inflammatory medications, as they can help to stop the arthritis from getting any worse. It can take a number of months for a DMARD to reach its full effect. However, they can often be taken at the same time as other first line medications, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and painkillers, to help ease symptoms whilst the DMARD begins to work. Most DMARDs work on the immune system and are designed to be taken long-term, and therefore there is a possibility of more significant side effects than with painkillers and NSAIDs alone.

2 When should DMARDs be prescribed? Psoriatic arthritis can cause irreversible damage to joints if effective DMARD treatment is not given when appropriate. There are two categories of DMARDs that are used for psoriatic arthritis traditional systemics, and the newer biologic treatments. Traditional systemic DMARDs (such as methotrexate, sulfasalazine, leflunomide) should be considered if: There is active psoriatic arthritis (i.e. inflammation is present in several joints despite using NSAIDs) The individual is unable to go about daily living, work or recreation easily Many joints are affected. Biologic Treatments should be considered if: The person has arthritis with three or more joints that are tender to touch and three or more joints that look or feel swollen, and at least two other traditional systemic DMARDs haven t worked or cannot be tolerated (ie. caused side effects that meant treatment had to be stopped). As with psoriasis, it is often a process of trial and error to find a treatment or combination of treatments that work well for each person with psoriatic arthritis. Because of this, a second biologic treatment should be tried if no acceptable improvement is seen after 12 weeks on an initial biologic. 2 The following is a brief summary of some of the commonly-prescribed DMARDs for psoriatic arthritis. You should always check with your doctor before taking any other medications (including vitamins or herbal supplements) whilst you are being prescribed any of the DMARDs below. Similarly, you should always ask your doctor for advice on drinking alcohol, getting pregnant or breastfeeding whilst taking one of these treatments. Further information on each of these treatments is available from the Psoriasis Association. Methotrexate (also referred to by its commercial names Matrex or Ebetrex) Methotrexate works to suppress the overactive immune system which causes inflammation, swelling and stiffness in psoriatic arthritis. Because of this suppression, a person taking methotrexate is likely to be more prone to infections. Methotrexate is usually taken in tablet form once a week, but in some cases it is given as an injection. It can take up to 12 weeks to become fully effective. People taking methotrexate will need regular blood tests to monitor liver and bone marrow function, and check for infections. They should also have an annual flu vaccination.

3 Methotrexate can also be used to treat psoriasis please see our Methotrexate information sheet for more in-depth information on this treatment. Sulfasalazine (also referred to by its commercial name Salazopyrin) Sulfasalazine reduces inflammation in the joints, and decreases pain, swelling and stiffness. Some people will start to notice results within a few weeks of starting the treatment, however, it may take around 12 weeks for sulfasalazine to have a full effect. Sulfasalazine is a tablet that is usually taken every day. The number and time to take your tablet will be explained to you by your doctor. The tablet has a special coating which means it dissolves more slowly, passing beyond the stomach before releasing its contents. This can help reduce nausea and stomach irritation associated with other treatments. You will need to have frequent blood tests for the first three months of taking the drug, followed by regular tests every three months, to monitor liver function and check for infections. You may also need an annual flu vaccination. Sulfasalazine may also turn your urine orange or dark yellow and your tears may be discoloured. This is nothing to worry about, however if you use extended wear contact lenses tell your doctor as they may develop an orange stain. Leflunomide (also referred to by its commercial name Arava) Leflunomide, like methotrexate was initially developed for use in the treatment of cancer. Leflunomide is an anti-t cell medication and as such is thought to control inflammation by interfering with T cell production of cytokines, similar to some of the biologics. It acts to suppress the overactive immune system, causing damage and pain to the joints. 3 Leflunomide is a tablet that is taken every day. Like other DMARDs, leflunomide does not work immediately it may be up to six weeks before you feel any effect and as long as six months before you feel the full benefit. The potential side effects of leflunomide are similar to methotrexate and so you will have regular blood and blood pressure tests, and may need an annual flu vaccination. Apremilast (also referred to by its commercial name Otezla) It is not known exactly how Otezla works in psoriasis or psoriatic arthritis. However, it is known that Otezla inhibits (ie. stops it from working as it usually does) an enzyme known as phosphodiesterase 4, or PDE4. PDE4 controls the inflammatory action within a cell, which can affect the level of inflammation associated with psoriasis or psoriatic arthritis. Helping to control this inflammation can lead to an improvement in symptoms for people with psoriasis or psoriatic arthritis.

4 Otezla is taken orally in tablet form twice a day. The dose is gradually increased over the first five days, until the patient is taking the full 30mg twice a day from day six onwards. Again, you will have regular monitoring tests, and may need an annual flu vaccination. Most people will need to have tried two of the more traditional systemic DMARDs before they can be offered apremilast to treat their psoriatic arthritis. Biologic Treatments A number of biologic treatments are available to treat psoriatic arthritis. There are various criteria for when biologic treatments can be prescribed to treat psoriatic arthritis, and for some treatments the criteria may vary if you are in Scotland compared to England or Wales. Please check the information sheet on each individual biologic treatment for more information about when it can be prescribed. The following treatments work in similar ways by suppressing a specific chemical called tumour necrosis factor-alpha (TNF-alpha) that is involved in triggering inflammation in the immune system. Cimzia is taken in two injections at weeks 0, 2 and 4, and then in one injection every two weeks. Treatment may be stopped if no significant results are seen within 12 weeks. Enbrel is usually taken once or twice a week by injection. Again, treatment may be stopped if no significant results are seen within 12 weeks. Humira is usually taken once every two weeks by injection. Again, treatment may be stopped if no significant results are seen within 12 weeks. Remicade is given in hospital using an intravenous drip into a vein (an infusion). Initially the infusions are given once at the beginning of treatment, after two weeks, and then after another four weeks. You will then need an infusion (which takes between one and two hours) every eight weeks. Again, treatment may be stopped if no significant results are seen within 12 weeks. Simponi is taken once a month by injection, on the same date each month. Again, treatment may be stopped if no significant results are seen within 12 weeks. 4 Stelara works in a slightly different way by slowing down the activity of interleukin 12 (IL-12) and interleukin 23 (IL-23), chemical messengers in the immune system that signal other cells to cause inflammation. It is usually taken by injection at week 0, week 4, and then every 12 weeks after that. Treatment may be stopped if no significant results are seen within 24 weeks. Cosentyx and Taltz also work on interleukin activity they bind to interleukin 17A (IL-17A) to inhibit (ie. stop it from working as it usually does) its inflammatory action. Cosentyx usually taken by two injections given at the same time, weekly for the first four weeks, and then every four weeks after that. Taltz is taken every other week until week 12, and then every four weeks after that.

5 As with the traditional systemic DMARDs, people taking biologic treatments will have regular blood tests and other checks, to monitor for side effects. As biologic treatments suppress the immune system, it is recommended that people taking them have an annual flu vaccination, as well as a pneumococcal vaccination before you start biologic treatment. Not all vaccinations, however, are safe to have when taking a biologic treatment, so you should always check with your Rheumatologist or another healthcare professional before having them. This is not a complete list of the second line treatments a Rheumatologist may prescribe for you; other treatments that are usually used for other forms of inflammatory arthritis may be prescribed on a case-by-case basis. More in-depth information on the treatments featured in this resource, and on first line treatments for psoriatic arthritis, is available from the Psoriasis Association. The information in this resource is not intended to replace that of a healthcare professional: If you have any concerns or questions about your treatment, do discuss this with your doctor and always read the patient information leaflet to make sure you are using them correctly. For more information, or for a list of resources used in the production of this information sheet, please contact the Psoriasis Association. 5 August 2018 (Review Date: 12/20)

Psoriatic Arthritis- Second Line Treatments

Psoriatic Arthritis- Second Line Treatments Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist

More information

Otezla. Otezla (apremilast) Description

Otezla. Otezla (apremilast) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background

More information

Psoriatic arthritis FACTSHEET

Psoriatic arthritis FACTSHEET 1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review

More information

Cosentyx. Cosentyx (secukinumab) Description

Cosentyx. Cosentyx (secukinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx

More information

A Patient s Guide to. Treatments for Psoriatic Arthritis

A Patient s Guide to. Treatments for Psoriatic Arthritis A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this

More information

Stelara. Stelara (ustekinumab) Description

Stelara. Stelara (ustekinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi

More information

Helpline No:

Helpline No: ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 DRUGS AND ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance

More information

RHEUMATOID ARTHRITIS DRUGS

RHEUMATOID ARTHRITIS DRUGS Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)

More information

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,

More information

Abatacept Drug information. Abatacept is used to treat rheumatoid arthritis.

Abatacept Drug information. Abatacept is used to treat rheumatoid arthritis. Abatacept Drug information Abatacept is used to treat rheumatoid arthritis. Abatacept should effectively treat your condition, and stop it causing damage to your joints. It has been tested and has helped

More information

Stelara. Stelara (ustekinumab) Description

Stelara. Stelara (ustekinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 6 Last Review Date: December 8, 2017 Stelara Description Stelara (ustekinumab)

More information

Methotrexate for inflammatory bowel disease: what you need to know

Methotrexate for inflammatory bowel disease: what you need to know Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or

More information

Drug information. Apremilast APREMILAST. is used to treat psoriasis and psoriatic arthritis. Helpline

Drug information. Apremilast APREMILAST. is used to treat psoriasis and psoriatic arthritis. Helpline Drug information Apremilast APREMILAST is used to treat psoriasis and psoriatic arthritis Helpline 0800 5200 520 1 Introduction Apremilast is a drug that can help prevent your condition causing damage

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)

More information

Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330

Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease

More information

Abatacept. What is abatacept?

Abatacept. What is abatacept? What is abatacept? Abatacept (trade name Orencia) is a type of drug called a biological therapy. It works by stopping the function of a particular cell in the immune system (called a T-cell). This prevents

More information

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the

More information

Ciclosporin. Drug information. Ciclosporin is used to treat rheumatoid arthritis, lupus, psoriatic arthritis and other conditions.

Ciclosporin. Drug information. Ciclosporin is used to treat rheumatoid arthritis, lupus, psoriatic arthritis and other conditions. Ciclosporin Drug information Ciclosporin is used to treat rheumatoid arthritis, lupus, psoriatic arthritis and other conditions. Ciclosporin should effectively treat your condition and prevent joint damage.

More information

apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.

apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

Infliximab Drug information. Infliximab can treat rheumatoid arthritis and psoriatic arthritis.

Infliximab Drug information. Infliximab can treat rheumatoid arthritis and psoriatic arthritis. Infliximab Drug information Infliximab can treat rheumatoid arthritis and psoriatic arthritis. Infliximab should effectively treat your condition, and stop it causing damage to your joints. It has been

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced

More information

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a

More information

Guidelines for rheumatology patients on biologic therapy. Rheumatology Department Patient Information Leaflet

Guidelines for rheumatology patients on biologic therapy. Rheumatology Department Patient Information Leaflet Guidelines for rheumatology patients on biologic therapy Rheumatology Department Patient Information Leaflet Introduction In general, people who have biologic therapy for their rheumatic condition (e.g.

More information

Certolizumab pegol (Cimzia) for psoriatic arthritis second line

Certolizumab pegol (Cimzia) for psoriatic arthritis second line Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date: Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

MEDICATION GUIDE. (tocilizumab)

MEDICATION GUIDE. (tocilizumab) MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1097-7 Program Prior Authorization/Notification Medication *Stelara (ustekinumab) *This program applies to the subcutaneous formulation

More information

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Psoriatic Arthritis (PsA) P&T DATE 2/15/2018 CLASS:

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Psoriatic Arthritis (PsA) P&T DATE 2/15/2018 CLASS: MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Psoriatic Arthritis (PsA) P&T DATE 2/15/2018 CLASS: LOB: Rheumatology/Anti-Inflammatory Disorders MCL REVIEW HISTORY 2/17,

More information

Public observer slides

Public observer slides Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple

More information

Biologics for Autoimmune Diseases

Biologics for Autoimmune Diseases Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines

More information

Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS

Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS Moderate to Severe Rheumatoid Arthritis (RA) 3 Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA (abatacept) is a prescription

More information

Tocilizumab Tocilizumab

Tocilizumab Tocilizumab Drug information Tocilizumab Tocilizumab This leaflet provides information on tocilizumab and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate

More information

First Name. Specialty: Fax. First Name DOB: Duration:

First Name. Specialty: Fax. First Name DOB: Duration: Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

More information

Center for Evidence-based Policy

Center for Evidence-based Policy P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N

More information

Seronegative Arthritis. Dr Mary Gayed 25 th April 2018

Seronegative Arthritis. Dr Mary Gayed 25 th April 2018 Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions

More information

Why have I been selected for treatment with adalimumab?

Why have I been selected for treatment with adalimumab? ADALIMUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about adalimumab (Humira TM ). It tells you what it is, how it works, how it is used to treat skin

More information

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014 Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT

More information

Azathioprine. Drug information. Azathioprine is used to treat rheumatoid arthritis, lupus and other conditions.

Azathioprine. Drug information. Azathioprine is used to treat rheumatoid arthritis, lupus and other conditions. Azathioprine Drug information Azathioprine is used to treat rheumatoid arthritis, lupus and other conditions. Azathioprine should help treat your condition. It has been in use for many years and has helped

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority Quality ID #410: Psoriasis: Clinical Response to Systemic Medications National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes Meaningful Measure Area: Management of Chronic

More information

KEEP UP THE FIGHT WITH. Little Victories

KEEP UP THE FIGHT WITH. Little Victories FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) KEEP UP THE FIGHT WITH Little Victories Small improvements in your daily activities may be a sign that ORENCIA (abatacept) is working for you. Use this

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab

More information

COSENTYX (secukinumab)

COSENTYX (secukinumab) COSENTYX (secukinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients

2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients 2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,

More information

Ustekinumab is used to treat moderate to severe plaque psoriasis in adults. Why have I been selected for treatment with ustekinumab?

Ustekinumab is used to treat moderate to severe plaque psoriasis in adults. Why have I been selected for treatment with ustekinumab? USTEKINUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about ustekinumab (Stelara TM ). It tells you what it is, how it works, how it is used to treat

More information

Anti-Tumor Necrosis Factor (Anti-TNF)

Anti-Tumor Necrosis Factor (Anti-TNF) Anti-Tumor Necrosis Factor (Anti-TNF) 110465 Anti-TNF.indd 1 9/20/16 9:01 AM s About your medicine Anti-tumor necrosis factor (anti-tnf) is a type of medicine called biologic agent that targets substance

More information

Dr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru

Dr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,

More information

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio

More information

Pharmacological Management of Knee Pain

Pharmacological Management of Knee Pain Pharmacological Management of Knee Pain Dr Indi Rasaratnam Consultant Rheumatologist, Epworth Health Care & The Alfred Senior Lecturer, Department of Medicine, Monash University Outline of Presentation

More information

Drug information. Secukinumab SECUKINUMAB. is used to treat psoriatic arthritis and ankylosing spondylitis. Helpline

Drug information. Secukinumab SECUKINUMAB. is used to treat psoriatic arthritis and ankylosing spondylitis. Helpline Drug information Secukinumab SECUKINUMAB is used to treat psoriatic arthritis and ankylosing spondylitis Helpline 0800 5200 520 1 Introduction Secukinumab is a drug that can help prevent your condition

More information

WHAT YOU SHOULD KNOW ABOUT RoACTEMRA

WHAT YOU SHOULD KNOW ABOUT RoACTEMRA RoACTEMRA (tocilizumab) IV and SC for Rheumatoid Arthritis WHAT YOU SHOULD KNOW ABOUT RoACTEMRA This brochure provides key information to assist in the patient s understanding of the benefits and risks

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs

More information

Horizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716

Horizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber

More information

USTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE

USTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)

More information

certolizumab pegol (Cimzia )

certolizumab pegol (Cimzia ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Actemra. Actemra (tocilizumab) Description

Actemra. Actemra (tocilizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra

More information

Psoriasis. and Biologic Treatments. Choose the best treatment to regain your quality of life. Edition 4

Psoriasis. and Biologic Treatments. Choose the best treatment to regain your quality of life. Edition 4 Psoriasis and Biologic Treatments Choose the best treatment to regain your quality of life. Edition 4 PSORIASIS, What is this disease? Psoriasis is a common disease, that affects up to 4% of the population.

More information

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

BACK FIGHT. It s time to. Take action today. Ask your rheumatologist about ORENCIA.

BACK FIGHT. It s time to. Take action today. Ask your rheumatologist about ORENCIA. For moderate to severe Rheumatoid Arthritis (RA) It s time to FIGHT BACK Model, not actual patient. Take action today. Ask your rheumatologist about ORENCIA. What is ORENCIA? ORENCIA (abatacept) is a prescription

More information

Drug information. Sarilumab SARILUMAB. is used to treat rheumatoid arthritis. Helpline

Drug information. Sarilumab SARILUMAB. is used to treat rheumatoid arthritis. Helpline Drug information Sarilumab SARILUMAB is used to treat rheumatoid arthritis Helpline 0800 5200 520 1 Introduction Sarilumab is a drug that can help prevent your condition causing damage to your body. You

More information

Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)

Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Otezla 10 mg film-coated tablets Otezla 20 mg film-coated tablets Otezla 30 mg film-coated tablets Apremilast This medicine is subject to additional monitoring.

More information

Psoriasis. and Biologic Treatments. Choose the best treatment to regain your quality of life.

Psoriasis. and Biologic Treatments. Choose the best treatment to regain your quality of life. Psoriasis and Biologic Treatments Choose the best treatment to regain your quality of life. PSORIASIS, What is this disease? Psoriasis is a common disease, that affects up to 4% of the population. It usually

More information

Information about... Infliximab. Ophthalmology Service Scottish Uveitis National Managed Clinical Network

Information about... Infliximab. Ophthalmology Service Scottish Uveitis National Managed Clinical Network Information about... Infliximab Ophthalmology Service Scottish Uveitis National Managed Clinical Network What is infliximab? Infliximab is a drug used in the treatment of inflammatory conditions including

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)

More information

MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)

MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not

More information

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid

More information

2017 Blue Cross and Blue Shield of Louisiana

2017 Blue Cross and Blue Shield of Louisiana Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Drug Class Review Targeted Immune Modulators

Drug Class Review Targeted Immune Modulators Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

o Your healthcare provider should test you for TB before starting CIMZIA.

o Your healthcare provider should test you for TB before starting CIMZIA. Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each

More information

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)?

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)? Humira (adalimumab) Medication Request Form (MRF) for Healthy Indiana Plan (HIP) and Hoosier Healthwise (HHW) FAX TO: (858) 790-7100 c/o MedImpact Healthcare Systems, Inc. Attn: Prior Authorization Department

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other GOLIMUMAB SIMPONI 22533, 22536, 34697, 35001 ROUTE = SUBCUTANE. GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a

More information

Get an Insurance Benefits Review for ORENCIA (abatacept)

Get an Insurance Benefits Review for ORENCIA (abatacept) Get an Insurance Benefits Review for ORENCIA (abatacept) If you and your doctor decide that ORENCIA is right for you, you can call 1-800-ORENCIA (1-800-673-6242) to do an Insurance Benefits Review. Our

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Quality ID #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier National Quality Strategy Domain:

More information

TOFACITINIB PATIENT INFORMATION ON. (Brand name: Xeljanz ) What is tofacitinib? Important things to remember

TOFACITINIB PATIENT INFORMATION ON. (Brand name: Xeljanz ) What is tofacitinib? Important things to remember PATIENT INFORMATION ON TOFACITINIB (Brand name: Xeljanz ) This information sheet has been produced by the Australian Rheumatology Association to help you understand the medicine that has been prescribed

More information

Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria

Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with

More information

Rheumatoid Arthritis Fact Sheet

Rheumatoid Arthritis Fact Sheet Rheumatoid Arthritis Fact Sheet This fact sheet is a summary of information found on ra.org.nz. Remember that each person is different and you should talk to your doctor about your disease and the best

More information

Why is this important for you? Types of arthritis. Information for the public Published: 28 February 2017 nice.org.uk

Why is this important for you? Types of arthritis. Information for the public Published: 28 February 2017 nice.org.uk Spondyloarthritis in over 16s: diagnosis and management Information for the public Published: 28 February 2017 nice.org.uk Spondyloarthritis: the care you should expect This information explains the care

More information

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has

More information

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,

More information

Appendix 1: Frequently Asked Questions

Appendix 1: Frequently Asked Questions Appendix 1: Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added to the Ontario Drug Benefit (ODB) Formulary

More information

3 rd Appraisal Committee meeting, 28 February 2017 Committee D

3 rd Appraisal Committee meeting, 28 February 2017 Committee D Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple Technology Appraisal 3 rd Appraisal Committee

More information

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi

More information

Drug information. Baricitinib BARICITINIB. is used to treat rheumatoid arthritis. Helpline

Drug information. Baricitinib BARICITINIB. is used to treat rheumatoid arthritis. Helpline Drug information Baricitinib BARICITINIB is used to treat rheumatoid arthritis Helpline 0800 5200 520 1 Introduction Baricitinib is a drug that can help prevent your condition causing damage to your body.

More information

Perioperative Medicine:

Perioperative Medicine: Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents

More information